ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. (2018)
Attributed to:
The Development of Inhibitors of Cdk Activating Kinase (CAK)
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/1535-7163.mct-16-0847
PubMed Identifier: 29545334
Publication URI: http://europepmc.org/abstract/MED/29545334
Type: Journal Article/Review
Volume: 17
Parent Publication: Molecular cancer therapeutics
Issue: 6
ISSN: 1535-7163